Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Minerals Ltd. is pleased to announce that its Ordinary Shares have been approved to trade on the OTCQB Venture Market in the United States of America and have commenced trading under the ticker ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

AlphaQuest LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 84.3% in the fourth quarter, according to its most recent filing with the SEC.

Read Our Latest Stock Report on VERX Vertex Stock Down 3.3 % Shares of NASDAQ:VERX opened at $32.88 on Friday. The stock has a market capitalization of $5.13 billion, a P/E ratio of 182.67, a PEG ...